The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Update on the Diagnosis and Management of Renal Angiomyolipoma
Abstract
PURPOSE: Advances in minimally invasive therapies and novel targeted chemotherapeutics have provided a breadth of options for the management of renal masses. Management of renal angiomyolipoma has not been reviewed in a comprehensive fashion in more than a decade. We provide an updated review of the current diagnosis and management strategies for renal angiomyolipoma. MATERIALS AND METHODS: We conducted a PubMed(®) search of all available literature for renal or kidney angiomyolipoma. Further sources were identified in the reference lists of identified articles. We specifically reviewed case series of partial nephrectomy, selective arterial embolization and ablative therapies as well as trials of mTOR inhibitors for angiomyolipoma from 1999 to 2014. RESULTS: Renal angiomyolipoma is an uncommon benign renal tumor. Although associated with tuberous sclerosis complex, these tumors occur sporadically. Risk of life threatening hemorrhage is the main clinical concern. Due to the fat content, angiomyolipomas are generally readily identifiable on computerized tomography and magnetic resonance imaging. However, fat poor angiomyolipoma can present a diagnostic challenge. Novel research suggests that various strategies using magnetic resonance imaging, including chemical shift magnetic resonance imaging, have the potential to differentiate fat poor angiomyolipoma from renal cell carcinoma. Active surveillance is the accepted management for small asymptomatic masses. Generally, symptomatic masses and masses greater than 4 cm should be treated. However, other relative indications may apply. Options for treatment have traditionally included radical and partial nephrectomy, selective arterial embolization and ablative therapies, including cryoablation and radio frequency ablation, all of which we review and update. We also review recent advances in the medical treatment of patients with tuberous sclerosis complex associated angiomyolipomas with mTOR inhibitors. Specifically trials of everolimus for patients with tuberous sclerosis complex suggest that this agent may be safe and effective in treating angiomyolipoma tumor burden. A schema for the suggested management of renal angiomyolipoma is provided. CONCLUSIONS: Appropriately selected cases of renal angiomyolipoma can be managed by active surveillance. For those patients requiring treatment nephron sparing approaches, including partial nephrectomy and selective arterial embolization, are preferred options. For those with tuberous sclerosis complex mTOR inhibitors may represent a viable approach to control tumor burden while conserving renal parenchyma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Curatolo, P., Bombardieri, R., & Jozwiak, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61279-9 · Cited by 1,088
Bissler, J. J., Kingswood, J. C., Radzikowska, E., Zonnenberg, B. A., Frost, M., Belousova, E., Sauter, M., Nonomura, N., Brakemeier, S., de Vries, P. J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61767-x · Cited by 880
Thompson, R. H., Boorjian, S. A., Lohse, C. M., Leibovich, B. C., Kwon, E. D., Cheville, J. C., & Blute, M. L. (2008) · Journal of Urology · doi:10.1016/j.juro.2007.09.077 · Cited by 713
Renal Angiomyolipoma: Relationships between Tumor Size, Aneurysm Formation, and Rupture
Yamakado, K., Tanaka, N., Nakagawa, T., Kobayashi, S., Yanagawa, M., & Takeda, K. (2002) · Radiology · doi:10.1148/radiol.2251011477 · Cited by 473
The Natural History of Renal Angiomyolipoma
Steiner, M. S., Goldman, S. M., Fishman, E. K., & Marshall, F. F. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35895-0 · Cited by 457
Contemporary Diagnosis and Management of Renal Angiomyolipoma
Nelson, C. P., & Sanda, M. G. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64440-0 · Cited by 420
Contemporary Diagnosis and Management of Renal Angiomyolipoma
NELSON, C. P., & SANDA, M. G. (2002) · The Journal of Urology · doi:10.1097/00005392-200210010-00004 · Cited by 384
Jinzaki, M., Silverman, S. G., Akita, H., Nagashima, Y., Mikami, S., & Oya, M. (2014) · Abdominal Imaging · doi:10.1007/s00261-014-0083-3 · Cited by 332
Davies, D. M., de Vries, P. J., Johnson, S. R., McCartney, D. L., Cox, J. A., Serra, A. L., Watson, P. C., Howe, C. J., Doyle, T., Pointon, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0445 · Cited by 309
Cited by
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
Metadata
- Authors
- Flum, A. S., Hamoui, N., Said, M. A., Yang, X. J., Casalino, D. D., McGuire, B. B., Perry, K. T., & Nadler, R. B.
- Venue
- Journal of Urology
- Published
- 2016-04
- Volume
- 195
- Issue
- 4 Part 1
- Pages
- 834-846
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2255561391
- Cited by
- 356
- References
- 19
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on the Diagnosis and Management of Renal Angiomyolipoma. https://app.cochat.ai/papers/10.1016/j.juro.2015.07.126
- The paper
- Flum, A. S., Hamoui, N., Said, M. A., Yang, X. J., Casalino, D. D., McGuire, B. B., Perry, K. T., & Nadler, R. B. (2016). Update on the Diagnosis and Management of Renal Angiomyolipoma. Journal of Urology. https://doi.org/10.1016/j.juro.2015.07.126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.